Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
Yu Fujiwara, Shumei Kato, Mary Nesline, et al.
Cancer Treatment Reviews (2022) Vol. 110, pp. 102461-102461
Open Access | Times Cited: 173

Showing 1-25 of 173 citing articles:

The cancer-immunity cycle: Indication, genotype, and immunotype
Ira Mellman, Daniel S. Chen, Thomas Powles, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2188-2205
Open Access | Times Cited: 355
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Qian Sun, Zhenya Hong, Cong Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 245
Nanomaterials in tumor immunotherapy: new strategies and challenges
Xudong Zhu, Shenglong Li
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 110
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 84
Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential
Yu-Ling Xiao, Yue Gong, Ying-Jia Qi, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 66
Self-driven nanoprodrug platform with enhanced ferroptosis for synergistic photothermal-IDO immunotherapy
Ping Huang, Yao Yang, Wenyan Wang, et al.
Biomaterials (2023) Vol. 299, pp. 122157-122157
Closed Access | Times Cited: 58
Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions
Chenyue Zhang, Chenxing Zhang, Haiyong Wang
Cancer Letters (2023) Vol. 562, pp. 216182-216182
Closed Access | Times Cited: 56
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity
Ruoxin Du, Xiangmei Zhang, Xiyan Lu, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100947-100947
Closed Access | Times Cited: 50
Endothelial cells in tumor microenvironment: insights and perspectives
Patrizia Leone, Eleonora Malerba, Nicola Susca, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 25
Tumor-induced metabolic immunosuppression: Mechanisms and therapeutic targets
Jean‐Ehrland Ricci
Cell Reports (2025) Vol. 44, Iss. 1, pp. 115206-115206
Closed Access | Times Cited: 3
New insight in immunotherapy and combine therapy in colorectal cancer
Kai Ji, Hang Jia, Zixuan Liu, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 2
Metabolic interplays between the tumour and the host shape the tumour macroenvironment
Patricia Altea‐Manzano, Amanda R. Decker-Farrell, Tobias Janowitz, et al.
Nature reviews. Cancer (2025)
Closed Access | Times Cited: 2
Nanomaterials: Breaking through the bottleneck of tumor immunotherapy
Yue Kang, Shenglong Li
International Journal of Biological Macromolecules (2023) Vol. 230, pp. 123159-123159
Closed Access | Times Cited: 38
Four Ounces Can Move a Thousand Pounds: The Enormous Value of Nanomaterials in Tumor Immunotherapy
Ziyin Chen, Ziqi Yue, Kaiqi Yang, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 26
Open Access | Times Cited: 31
Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials
Hemaasri-Neya Girithar, Ananda Staats Pires, Seong Beom Ahn, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 2, pp. 185-203
Open Access | Times Cited: 25
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
Ginette S. Santiago-Sánchez, Kellsye P. Fabian, James W. Hodge
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 15
A Review of Current and Pipeline Drugs for Treatment of Melanoma
Nicole Natarelli, Soo Aleman, Isabella Mark, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 214-214
Open Access | Times Cited: 15
FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity
Enni Chen, Jiawei Wu, Jiajia Huang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
OX40/OX40 ligand and its role in precision immune oncology
Bicky Thapa, Shumei Kato, Daisuke Nishizaki, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 3, pp. 1001-1013
Open Access | Times Cited: 12
Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer
Jing Yan, Di Chen, Zi Ye, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Closed Access | Times Cited: 11
Viewing the immune checkpoint VISTA: landscape and outcomes across cancers
Daisuke Nishizaki, Razelle Kurzrock, Hirotaka Miyashita, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102942-102942
Open Access | Times Cited: 10
A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer
Pengyu Yao, Liang Su, Zhenying Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
The AHR–NRF2–JDP2 gene battery: Ligand–induced AHR transcriptional activation
Kenly Wuputra, Wen-Hung Hsu, Chia‐Chen Ku, et al.
Biochemical Pharmacology (2025) Vol. 233, pp. 116761-116761
Open Access | Times Cited: 1
Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cells
Irene Kang, George Theodoropoulos, Medhi Wangpaichitr
Frontiers in Oncology (2025) Vol. 14
Open Access | Times Cited: 1
Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges
S. A. Tilakaratne Bandara, Sreejith Raveendran
Cancers (2025) Vol. 17, Iss. 5, pp. 821-821
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top